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Abstract 
Objective: This study analyzes differences between HIV statistics in Hispanic American 
countries that have passed UHC legislation versus those that have not passed UHC legislation. In 
2017, 0.4% of the population of Latin America and 1.2% of the population of the Caribbean was 
living with Human Immunodeficiency Virus (HIV).1 Because of these high rates of HIV in 
Hispanic America, as well as the lethality of HIV if untreated, HIV statistics and treatment 
outcomes in Hispanic America are of great concern. Relationships between HIV statistics and 
Universal Health Coverage (UHC) legislation could serve as a metric for UHC performance in 
Hispanic American countries. Methods: The HIV statistics analyzed are HIV prevalence, HIV 
incidence, number of acquired immune deficiency syndrome (AIDS) related deaths, percent of 
people with HIV receiving anti-retroviral therapy (ART), 12-month retention on ART, mother-
to-child HIV transmission rate, percent of people living with HIV whose deaths were averted due 
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to ART, and percent of people living with HIV who have suppressed viral loads. HIV/AIDS data 
for this study was found from UNAIDS,1 and the UHC legislation data was found from WHO’s 
Global Health Observatory.2 Data was analyzed with independent t-tests to compare HIV 
statistics in countries that have passed UHC legislation versus those that have not passed UHC 
legislation. Results: Countries that have passed UHC legislation have significantly higher 
prevalence (p = .04) and incidence (p = .02) of HIV than countries that have not passed UHC 
legislation. Countries that have passed UHC legislation have significantly less deaths due to 
AIDS (p = .03).  
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Introduction/Literature Review  
In Latin America, 1,900,000 people [1,500,000-2,300,000], or 0.4% [0.3%-0.5%] of the 
population, were living with HIV in 2017.1 In the Caribbean in 2017, 330,000 people [280,000-
390,000], or 1.2% [1.0%-1.4%] of the population, were living with HIV.1 Because of these high 
rates of HIV in Hispanic America, as well as the lethality of HIV if untreated, HIV rates and 
treatment outcomes in Hispanic America are of great concern. HIV causes a decrease in the 
number of CD4+ T cells, which leads to increased risk of infections and cancer.3 Opportunistic 
infections that take place among HIV patients with decreased CD4+ counts are often the cause of 
death for HIV patients, but opportunistic infections and AIDS-related deaths are often 
preventable with modern antiretroviral therapy (ART).  
Upon review of the literature, we did not find any studies examining the relationship between 
UHC legislation and HIV outcomes; as such, this study bridges a gap in our understanding of the 
relationship between HIV outcomes and universal health coverage legislation. Nonetheless, 
related research indicates that increased insurance coverage and government spending on health 
lead to improved outcomes. Use of medical services increases among people with higher level of 
insurance coverage.4-6 Increased use of medical services may improve patient outcomes due to 
increased consultation and intervention from healthcare professionals, as well as preventative 
care. In a study on a health insurance program for impoverished Colombians, increased use of 
preventative care through the program led to fewer sick days and fewer ill symptoms in pediatric 
patients.7 UHC allows for improved access to preventative care, so UHC legislation may produce 
similar results as the Colombian health insurance program study. In addition, population health 
outcomes tend to be better in countries with higher government spending and increased pooled 
health financing,8-10 suggesting that UHC could improve population health outcomes. Therefore, 
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we hypothesized that countries that have passed UHC legislation would have more favorable 
HIV outcomes, such as lower HIV prevalence and incidence, fewer AIDS-related deaths, higher 
percent of HIV patients receiving ART, higher retention in ART, lower mother-to-child 
transmission rate, more deaths averted due to ART, and a higher percent of patients with 
suppressed viral load.  
Hypothesis/Specific Aims/Research Questions 
The eight research questions addressed in this project are listed below. 
1. How does UHC legislation in Hispanic American countries affect the percent of 
population living with HIV? 
2. How does UHC legislation in Hispanic American countries affect incidence of HIV? 
3. How does UHC legislation in Hispanic American countries affect the percent people 
living with HIV that die AIDS-related deaths? 
4. How does UHC legislation in Hispanic American countries affect the number of people 
on ART? 
5. How does UHC legislation in Hispanic American countries affect 12-month retention on 
antiretroviral therapy? 
6. How does UHC legislation in Hispanic American countries affect mother-to-child HIV 
transmission rate?  
7. How does UHC legislation in Hispanic American countries affect number of deaths 
averted due to ART? 
8. How does UHC legislation in Hispanic American countries affect percent of people 





HIV/AIDS data for this study was found from UNAIDS,1 and the Universal Health Coverage 
data was found from WHO’s Global Health Observatory.2 Due to data being derived from 
publicly available data sets, IRB approval was not required.  
UNAIDS develops their HIV/AIDS estimates with teams consisting of epidemiologists, 
demographers, monitoring and evaluation specialists, and technical partners.11 The software used 
by UNAIDS to create estimate models are Spectrum from Avenir Health and the Estimates and 
Projections Package from East-West Center.11 In countries of high rates of HIV transmission, 
HIV prevalence estimates are gathered from nationally representative population-based surveys 
and antenatal clinic attendance surveillance. In countries of low-level HIV epidemic, estimates 
are gathered from empirical data about high-risk populations. Surveys and data of pregnant 
women who attend antenatal clinics are used for determining estimates of HIV prevalence 
among low-risk populations within these low-level HIV epidemic countries. Countries in Latin 
America and the Caribbean have insufficient antenatal clinic surveillance data and population-
based survey data, so data is gathered from registration and disease reporting systems. In these 
countries, HIV case reports and data on AIDS-related deaths are used directly to determine 
estimates.11 
 The WHO Global Health Observatory data on countries that have passed UHC legislation 
was gathered from a 2013 study by Feigl and Ding.12 This study used databases and legal 
healthcare documents to collect data. Feigl and Ding developed a new indicator to classify 
countries with universal health coverage and called this indicator “evidenced formal coverage” 
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(EFC). Countries qualified as having EFC if they had legislated UHC, had a formal coverage rate 
of ≥85%, and had ≥90% access to skilled attendance at birth.12 This study considers the first 
passage of any UHC legislation to be the marker of UHC coverage, but most countries do not 
convert to a completely UHC health system with the passage of the first UHC-related legislation. 
Percent of population with healthcare coverage was determined from two International Labor 
Office reports.12 To determine whether countries had passed UHC legislation, Feigl and Ding 
searched databases and healthcare legal documents of governments of the countries studied. If 
the legislation included language that indicated that all citizens were covered by the health plan, 
the researchers determined that the country had legal coverage.12  
Data Collection 
We chose to analyze the HIV statistics and UHC legislation in Hispanic America. Hispanic 
America consists of the predominantly Spanish-speaking countries of Latin America and the 
Caribbean. These countries include Argentina, Bolivia, Chile, Colombia, Costa Rica, Cuba, the 
Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, 
Paraguay, Peru, Puerto Rico, Uruguay, and Venezuela.  
Not all countries included in the study had complete data for every variable. Any country that 
lacked a data point for a given variable was excluded from analysis of that variable. Puerto Rico 
lacked data for all variables and was excluded from the entire study. Nineteen countries were 
included in this study. 
Data Analysis 
We conducted independent t-tests for each of the eight research questions to compare 
HIV statistics in Hispanic American countries that have passed UHC legislation versus those 
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that have not passed UHC legislation. The independent variables were presence or absence of 
UHC legislation, so countries were split into groups “yes” (those that have passed UHC 
legislation) and “no” (those that have not passed UHC legislation). The dependent variables 
were HIV prevalence (%), HIV incidence (per 1000 population), percent of those living with 
HIV who died AIDS-related deaths, percent of people living with HIV whose deaths were 
averted due to ART, percent of people living with HIV receiving ART, mother-to-child 
transmission rate, 12-month retention on ART (%), and percent of people living with HIV 
who have suppressed viral load. Hispanic American countries that have passed UHC 
legislation are Argentina, Bolivia, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, 
Ecuador, Panama, El Salvador, Uruguay, and Venezuela. Hispanic American countries that 




The mean prevalence was significantly higher in countries that have passed UHC legislation 
(Table; mean “yes UHC” 0.527%; mean “no UHC” 0.317%; p = .04). The mean incidence of 
HIV diagnoses per 1000 people in the population was also significantly higher in countries that 
have passed UHC legislation (Table; mean “yes UHC” 0.346; mean “no UHC” 0.173; p = .02). 
The mean percent of people living with HIV who died due to AIDS-related deaths was 
significantly lower in countries that have passed UHC (Table; mean “yes UHC” 0.019; mean “no 






There was a statistically significant difference in mean HIV prevalence, incidence, and 
AIDS-related deaths in Hispanic American countries that have passed UHC legislation compared 
Table: HIV Outcomes and UHC Legislation   
UHC legislation* N** Mean Std. Deviation P value 
HIV Prevalence (%) Yes 11 0.527*** 0.205 .04 
 
  No 6 0.317 0.117  
HIV Incidence per 1000 Population Yes 11 0.346*** 0.151 .02 
 
  No 6 0.173 0.077  
Percent of People Living with HIV who 
Died AIDS-Related Deaths 
Yes 9 0.019*** 0.007 .03 
  No 5 0.033 0.015  
Percent of People Living with HIV 
whose Deaths were Averted due to ART 
Yes 9 0.033 0.008 .85 
  No 5 0.032 0.012  
Percent of People Living with HIV 
Receiving ART 
Yes 11 51.82 8.097 .66 
  No 6 49.67 11.501  
Mother-to-Child Transmission Rate Yes 10 12.103 6.363 .12 
  No 6 17.630 6.774  
12 Month Retention on ART (%) Yes 6 81.670 15.629 .36 
  No 5 71.600 18.929  
Percent of People Living with HIV with 
Suppressed Viral Load 
Yes 5 35.800 7.887 .76 
  No 4 37.750 10.436  
Legend for Table:  
* UHC legislation, Yes: countries that have passed UHC legislation;  
UHC legislation, No: countries that have not passed UHC legislation 
** N: Number of countries included for analysis 
*** Significantly different from countries with no UHC legislation (p < .05) 




to Hispanic American countries that have not passed UHC legislation. Two of the three 
statistically significant results refuted our hypothesis that countries that have passed UHC 
legislation would have more favorable HIV outcomes.  We hypothesized that countries that had 
passed UHC legislation would have lower prevalence and incidence of HIV than countries that 
have not passed UHC legislation, but the data refute this hypothesis. Instead, countries that have 
passed UHC legislation have statistically significantly higher prevalence and incidence of HIV 
(Table). The data support our hypothesis that there are fewer AIDS-related deaths among HIV 
patients in countries that have passed UHC legislation (Table). No statistically significant 
differences were found for mean deaths averted due to ART, percent of people living with HIV 
receiving ART, mother-to-child transmission rate, 12-month retention on ART, or percent of 
people living with HIV who have suppressed viral load (Table). Further research is needed to 
understand why Hispanic American countries with UHC legislation had higher prevalence and 
incidence of HIV. One potential consideration for decreased prevalence and incidence of HIV in 
countries without UHC legislation may be that decreased insurance coverage and healthcare 
access leads to decreased rates of testing for HIV, resulting in underreported prevalence and 
incidence of HIV. 
The data suggest that universal health coverage legislation does not have a positive impact on 
HIV outcomes, except that it may lead to decreased AIDS-related deaths among HIV patients. 
Our findings contradict the current literature, which suggests that increased insurance coverage 
leads to increased medical service use, fewer sick days, and improved public health 
outcomes.4,7,8  
A major limitation faced in this study was lack of availability of data. Some countries did not 
have data available for various data points. Venezuela had a lack of data for many of the research 
Frantz 10 
 
questions investigated in this study. Although there were 19 countries included in this study, only 
as many as 17 countries had data on a given statistic, such as prevalence, and as few as only 9 of 
the 19 countries had available data for percent of HIV patients with suppressed viral load. 
Another limitation faced in this study was an incomplete understanding of universal health 
coverage in each country. The study that we used to provide UHC legislation data considered a 
country to have UHC if there had been any legislation indicating any level of UHC; there is 
likely a discrepancy in amount of coverage between countries. It was not feasible to quantify 
ease of access in each country, percent of the population that had coverage through each 
country’s UHC plan, or what medical services that the UHC plan covered.  
Future research should further investigate the relationship between UHC legislation and HIV 
outcomes, since the results from this study and findings from other studies about increased 
insurance coverage are contradictory. Other related future directions include investigating HIV 
outcomes compared to prevalence of homophobia and HIV stigma in various locations 
worldwide. 
Conclusion 
Countries with UHC legislation have significantly fewer deaths due to AIDS (p = .03), but 
prevalence and incidence of HIV are significantly higher in countries with UHC legislation (p = 
.04 and p = .02, respectively). Some research indicates improved health outcomes with increased 
insurance coverage or government health spending,4,7,8 suggesting a potential link between UHC 
legislation and health outcomes. Since HIV is highly prevalent in Hispanic America, 
investigating the relationship between UHC legislation and HIV outcomes could serve as a 
metric for performance of UHC legislation. This could shape health policymaking, but more 
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